In addition, parthenolide and epigallocatechin 3-gallate showed the capacity to inhibit obesity and obesity-induced inflammatory responses via NRF2/KEAP1 signaling under HFD conditions [68,69]. Here, KEAP1 is linked to obesity disorder.